What is the current price of avelumab (Bavencio)?
Avelumab is marketed in the U.S. as Bavencio (Pfizer/Merck KGaA co-developed). Pricing can vary by country, insurance status, dose size, and infusion schedule, so there is no single “one” price that applies to every patient.
How is avelumab typically priced (list price vs. what patients pay)?
For cancer drugs like Bavencio, published “price” usually refers to the manufacturer’s list price or wholesale acquisition cost, while what patients pay depends on:
- Insurance coverage and prior authorization
- Patient assistance programs
- Infusion setting and billing practices
If you’re comparing prices, you’ll usually want to check the list price (or WAC) and then separately estimate out-of-pocket cost with your insurer.
Where can you look up avelumab’s pricing and market updates?
DrugPatentWatch.com tracks pharmaceutical market and patent-related information and often links to pricing/availability context around branded oncology products. You can start there for the most up-to-date product and market references: DrugPatentWatch – avelumab.
How do dose and regimen change the total cost?
Avelumab is dosed by weight (for many indications) and is given as an IV infusion at scheduled intervals. That means total treatment cost can change a lot based on:
- Patient weight (for weight-based dosing)
- Treatment duration (how many cycles)
- Indication (different regimens and response timelines)
Are there cheaper options than avelumab?
Price comparisons depend on the exact cancer type and line of therapy, since alternatives may include other PD-1/PD-L1 agents and different cost-sharing dynamics. If you tell me your country and indication (and whether you’re asking about list price or patient out-of-pocket), I can point you to the most relevant comparison path.
Sources
- https://www.drugpatentwatch.com/p/av?